Holen Sie sich die Stockscreener-App
61.09
0.21%
0.13
Schlusskurs vom Vortag:
$60.96
Offen:
$60.92
24-Stunden-Volumen:
1.76M
Relative Volume:
1.46
Marktkapitalisierung:
$4.85B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-10.28
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
+6.69%
1M Leistung:
+34.95%
6M Leistung:
+13.95%
1J Leistung:
+86.82%
1-Tages-Spanne:
$60.48
$62.18
1-Wochen-Bereich:
$56.51
$62.18
52-Wochen-Spanne:
$33.19
$62.18
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
61.09 | 4.63B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics (NASDAQ:PTCT) Sets New 1-Year HighHere's Why - MarketBeat
Can PTC Therapeutics Inc. stock continue upward trendJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Ptc Therapeutics stock hits 52-week high at 61.17 USD - Investing.com
Bayforest Capital Ltd Purchases New Shares in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Shares Acquired by Parkman Healthcare Partners LLC - MarketBeat
Insider Sell: David Southwell Sells 12,000 Shares of PTC Therape - GuruFocus
Eric Pauwels Sells 39,850 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU - Insider Monkey
Adage Capital Partners GP L.L.C. Has $30.32 Million Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AQR Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Insider Sell Alert: Eric Pauwels Sells 39,850 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
How sensitive is PTC Therapeutics Inc. to inflationJuly 2025 Recap & AI Based Buy and Sell Signals - Lancaster City Council
Bank of America Securities Keeps Their Buy Rating on PTC Therapeutics (PTCT) - The Globe and Mail
Canada Pension Plan Investment Board Raises Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
PTC Therapeutics at Morgan Stanley Conference: Strategic Insights and Updates - Investing.com Canada
PTC Therapeutics To Challenge BioMarin's Metabolic Disorder TreatmentBioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $76 - 富途牛牛
Can PTC Therapeutics Inc. Overcome Bearish Sentiment2025 Short Interest & Technical Entry and Exit Tips - beatles.ru
Volume Surge May Signal Institutional Interest in PTC Therapeutics Inc.Trade Ideas & AI Enhanced Trade Execution Alerts - beatles.ru
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Shares Bounce 26% But Its Business Still Trails The Industry - simplywall.st
PTC Therapeutics (NASDAQ:PTCT) Director Sells $83,600.05 in Stock - MarketBeat
PDT Partners LLC Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT is Palo Alto Investors LP's 8th Largest Position - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Trading 6.1% HigherStill a Buy? - MarketBeat
PTC Therapeutics, Inc. $PTCT Shares Acquired by Ieq Capital LLC - MarketBeat
Real time scanner hits for PTC Therapeutics Inc. explained2025 Risk Factors & AI Based Buy and Sell Signals - Newser
Heatmap analysis for PTC Therapeutics Inc. and competitorsJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
What institutional flow reveals about PTC Therapeutics Inc.July 2025 Reactions & Short-Term High Return Strategies - Newser
Is PTC Therapeutics Inc. stock a good pick for beginners2025 Sector Review & Weekly Setup with ROI Potential - خودرو بانک
What to expect from PTC Therapeutics Inc. in the next 30 daysJuly 2025 Setups & Entry Point Confirmation Signals - Newser
Is now a turning point for PTC Therapeutics Inc.Earnings Beat & Safe Entry Zone Identification - Newser
Ptc Therapeutics stock hits 52-week high at 58.61 USD By Investing.com - Investing.com Canada
PTC Therapeutics, Inc. $PTCT Position Trimmed by Armistice Capital LLC - MarketBeat
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges - MSN
Technical analysis overview for PTC Therapeutics Inc. stockQuarterly Trade Summary & Consistent Profit Trading Strategies - Newser
Applying Wyckoff theory to PTC Therapeutics Inc. stock2025 Winners & Losers & Long-Term Growth Plans - Newser
Real time alert setup for PTC Therapeutics Inc. performanceMarket Trend Summary & Free Weekly Watchlist of Top Performers - Newser
What is PTC Therapeutics Inc.’s valuation compared to sectorJuly 2025 Weekly Recap & Risk Controlled Swing Alerts - خودرو بانک
Institutional scanner results for PTC Therapeutics Inc.Stop Loss & Verified Short-Term Trading Plans - Newser
Ptc Therapeutics stock hits 52-week high at 58.61 USD - Investing.com
Transcript : PTC Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 11 - MarketScreener
Here's Why Shares in PTC Therapeutics Soared This Week - Mitrade
PTCT Stock Surges After Promising Outlook for Sephience - GuruFocus
Transcript : PTC Therapeutics, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 08 - MarketScreener
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):